Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World American Journal of Hematology Aplastic Anemia
Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria Hamostaseologie Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies Blood Advances Paroxysmal Nocturnal Hemoglobinuria (PNH)
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry Haematologica Myelodysplastic Syndromes (MDS)
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study Blood Cancer Journal Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome BioDrugs Paroxysmal Nocturnal Hemoglobinuria (PNH)
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia Blood Cancer Journal Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.